Regeneron Pharmaceuticals, Inc.

Medical, Industry Outlook

Businesswire | August 11, 2023

TriSalus Life Sciences® Inc. an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech). TriSalus’ common stock and warrants are expected to commence trading on the Nasdaq Global Market under the ticker symbols “TLSI” and “TLSIW,” respectiv...

Cell and Gene Therapy

Lunaphore and Nucleai | September 09, 2022

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. “We are thrilled to announce the partnership with Lunaphore and...

Industry Outlook

prnewswire | May 08, 2023

Frost & Sullivan announced that it has awarded Genomenon with the 2023 Global Technology Innovation Leadership Award. Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables. Frost & Sullivan market analysts determined that Genomenon excels in many of the cri...

MedTech

Genscript | August 18, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks. mRNA provides new therapeutic opportunities for a range of diseases, and s...